# A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus

> **NCT00254254** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 13 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Exenatide - Exenatide - Placebo
- **DRUG:** Exenatide - Placebo - Exenatide
- **DRUG:** Placebo - Exenatide - Exenatide

## Key facts

- **NCT ID:** NCT00254254
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-02-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254254, "A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00254254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*